Inhaled Biologics: From Preclinical to Product Approval

Author(s): Kristin Fathe, Silvia Ferrati, Daniel Moraga-Espinoza, Ashkan Yazdi, Hugh D.C. Smyth

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 17 , 2016

Become EABM
Become Reviewer


Background: Delivery of pharmacologically active compounds to the lung for systemic effects is well known and recently has entered a new era with several products achieving regulatory approval. This review focuses on the barriers to pulmonary delivery of biologics. Methods: Lessons learned from the development of recently approved products will be reviewed to shed light on the current challenges that are faced when developing biological products for inhaled delivery. Results: The text and tables presented herein consolidate the current data and ongoing research regarding biological, inhaled products. Conclusion: With this basis, we also review the future prospects for pulmonary delivery of biologics for systemic delivery and how the biological and physical barriers may be overcome.

Keywords: Systemic pulmonary delivery, biologics, inhalation devices.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [2501 - 2521]
Pages: 21
DOI: 10.2174/1381612822666160210142910
Price: $65

Article Metrics

PDF: 138
HTML: 14
PRC: 1